Novo Nordisk shares fell sharply after it said a pill with the key ingredient in Ozempic and Wegovy didn’t slow Alzheimer’s disease in two late-stage clinical trials.
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials
Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two late-stage clinical trials.
